Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.

The Journal of pathology - 1 Jan 2014

Ardighieri Laura, Zeppernick Felix, Hannibal Charlotte G, Vang Russell, Cope Leslie, Junge Jette, Kjaer Susanne K, Kurman Robert J, Shih Ie-Ming

Abstract excerpt

There is debate as to whether peritoneal implants associated with serous borderline tumours/atypical proliferative serous tumours (SBT/APSTs) of the ovary are derived from the primary ovarian tumour or arise independently in the peritoneum. We analysed 57 SBT/APSTs from 45 patients with advanced-stage disease identified from a nation-wide tumour registry in Denmark. Mutational analysis for hotspots in KRAS and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystadenocarcinoma, Serous
Share to Denmark

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Laser Capture Microdissection

Share to Ovarian Neoplasms

Share to Peritoneal Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24307542
DOI: 10.1002/path.4293
PMCID: PMC4086471

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.PMID 24307542Read ↗

KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.Semantic proximity Read ↗

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.Semantic proximity Read ↗

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.Semantic proximity Read ↗

KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.Semantic proximity Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior.Semantic proximity Read ↗

Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants.Semantic proximity Read ↗

Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.Semantic proximity Read ↗

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.Semantic proximity Read ↗

Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.Semantic proximity Read ↗

Low‐grade serous carcinomas of the ovary contain very few point mutationsSemantic proximity Read ↗

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.